Literature DB >> 34505972

GPR40 Agonist Ameliorate Pathological Neuroinflammation of Alzheimer's Disease via the Modulation of Gut Microbiota and Immune System, a Mini-Review.

Jianheng Chen1, Qian Li2, Jiang Zhu2, Zijing Yuan2, Tao Wang2, Jie Song3.   

Abstract

Alzheimer's disease (AD) is a central disease with high incidence, and its pathological process is closely associated with changes of some biological indicators in the periphery. Among them, the intestinal flora mainly causes a series of pathological changes such as inflammation through the immune system, which may contribute to the pathological process of AD. In this paper, we mainly focused the relationship between gut microbiota and immune system disorder in the neuropathology of AD, underlining the significance of the advanced mechanism of inflammatory response and providing a new direction for the treatment of AD.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Alzheimer’s disease; GPR40; Gut microbiota; Neuroinflammation

Mesh:

Substances:

Year:  2021        PMID: 34505972     DOI: 10.1007/s12640-021-00408-z

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  65 in total

Review 1.  The Cellular Phase of Alzheimer's Disease.

Authors:  Bart De Strooper; Eric Karran
Journal:  Cell       Date:  2016-02-11       Impact factor: 41.582

Review 2.  Homeostatic Immunity and the Microbiota.

Authors:  Yasmine Belkaid; Oliver J Harrison
Journal:  Immunity       Date:  2017-04-18       Impact factor: 31.745

3.  γ-Aminobutyric acid production by culturable bacteria from the human intestine.

Authors:  E Barrett; R P Ross; P W O'Toole; G F Fitzgerald; C Stanton
Journal:  J Appl Microbiol       Date:  2012-06-15       Impact factor: 3.772

Review 4.  Role of inflammatory molecules in the Alzheimer's disease progression and diagnosis.

Authors:  Eva Bagyinszky; Vo Van Giau; Kyuhwan Shim; Kyoungho Suk; Seong Soo A An; SangYun Kim
Journal:  J Neurol Sci       Date:  2017-03-22       Impact factor: 3.181

5.  Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils.

Authors:  Mahiuddin Ahmed; Judianne Davis; Darryl Aucoin; Takeshi Sato; Shivani Ahuja; Saburo Aimoto; James I Elliott; William E Van Nostrand; Steven O Smith
Journal:  Nat Struct Mol Biol       Date:  2010-04-11       Impact factor: 15.369

6.  The effects of exercise on hypothalamic neurodegeneration of Alzheimer's disease mouse model.

Authors:  Khoa Do; Brenton Thomas Laing; Taylor Landry; Wyatt Bunner; Naderi Mersaud; Tomoko Matsubara; Peixin Li; Yuan Yuan; Qun Lu; Hu Huang
Journal:  PLoS One       Date:  2018-01-02       Impact factor: 3.240

7.  Key Aging-Associated Alterations in Primary Microglia Response to Beta-Amyloid Stimulation.

Authors:  Cláudia Caldeira; Carolina Cunha; Ana R Vaz; Ana S Falcão; Andreia Barateiro; Elsa Seixas; Adelaide Fernandes; Dora Brites
Journal:  Front Aging Neurosci       Date:  2017-08-31       Impact factor: 5.750

Review 8.  Alzheimer's Disease and Type 2 Diabetes: A Critical Assessment of the Shared Pathological Traits.

Authors:  Shreyasi Chatterjee; Amritpal Mudher
Journal:  Front Neurosci       Date:  2018-06-08       Impact factor: 4.677

Review 9.  LPS-induced Murine Neuroinflammation Model: Main Features and Suitability for Pre-clinical Assessment of Nutraceuticals.

Authors:  Miryam Nava Catorce; Goar Gevorkian
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

10.  ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.

Authors:  Jeffrey L Cummings; Sharon Cohen; Christopher H van Dyck; Mark Brody; Craig Curtis; William Cho; Michael Ward; Michel Friesenhahn; Christina Rabe; Flavia Brunstein; Angelica Quartino; Lee A Honigberg; Reina N Fuji; David Clayton; Deborah Mortensen; Carole Ho; Robert Paul
Journal:  Neurology       Date:  2018-04-25       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.